Literature DB >> 25301560

Ceruloplasmin has two nearly identical sites that bind myeloperoxidase.

Bakytzhan Bakhautdin1, Esen Goksoy Bakhautdin2, Paul L Fox3.   

Abstract

Ceruloplasmin (Cp) is a copper-containing ferroxidase with potent antioxidant activity. Cp is expressed by hepatocytes and activated macrophages and has been known as physiologic inhibitor of myeloperoxidase (MPO). Enzymatic activity of MPO produces anti-microbial agents and strong prooxidants such as hypochlorous acid and has a potential to damage host tissue at the sites of inflammation and infection. Thus Cp-MPO interaction and inhibition of MPO has previously been suggested as an important control mechanism of excessive MPO activity. Our aim in this study was to identify minimal Cp domain or peptide that interacts with MPO. We first confirmed Cp-MPO interaction by ELISA and surface plasmon resonance (SPR). SPR analysis of the interaction yielded 30nM affinity between Cp and MPO. We then designed and synthesized 87 overlapping peptides spanning the entire amino acid sequence of Cp. Each of the peptides was tested whether it binds to MPO by direct binding ELISA. Two of the 87 peptides, P18 and P76 strongly interacted with MPO. Amino acid sequence analysis of identified peptides revealed high sequence and structural homology between them. Further structural analysis of Cp's crystal structure by PyMOL software unfolded that both peptides represent surface-exposed sites of Cp and face nearly the same direction. To confirm our finding we raised anti-P18 antisera in rabbit and demonstrated that this antisera disrupts Cp-MPO binding and rescues MPO activity. Collectively, our results confirm Cp-MPO interaction and identify two nearly identical sites on Cp that specifically bind MPO. We propose that inhibition of MPO by Cp requires two nearly identical sites on Cp to bind homodimeric MPO simultaneously and at an angle of at least 120degrees, which, in turn, exerts tension on MPO and results in conformational change.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ceruloplasmin; Inhibition; Interaction; Myeloperoxidase

Mesh:

Substances:

Year:  2014        PMID: 25301560      PMCID: PMC4253670          DOI: 10.1016/j.bbrc.2014.09.134

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  22 in total

1.  Bactericidal effect of Fe2+, ceruloplasmin, and phosphate.

Authors:  S J Klebanoff
Journal:  Arch Biochem Biophys       Date:  1992-06       Impact factor: 4.013

Review 2.  Living with a killer: the effects of hypochlorous acid on mammalian cells.

Authors:  J M Pullar; M C Vissers; C C Winterbourn
Journal:  IUBMB Life       Date:  2000 Oct-Nov       Impact factor: 3.885

3.  Transcriptional regulation of ceruloplasmin gene expression during inflammation.

Authors:  J D Gitlin
Journal:  J Biol Chem       Date:  1988-05-05       Impact factor: 5.157

4.  Mechanisms of hypochlorite injury of target cells.

Authors:  I U Schraufstätter; K Browne; A Harris; P A Hyslop; J H Jackson; O Quehenberger; C G Cochrane
Journal:  J Clin Invest       Date:  1990-02       Impact factor: 14.808

5.  Binding and inhibition of myeloperoxidase (MPO): a major function of ceruloplasmin?

Authors:  M Segelmark; B Persson; T Hellmark; J Wieslander
Journal:  Clin Exp Immunol       Date:  1997-04       Impact factor: 4.330

6.  3-Chlorotyrosine as a marker of protein damage by myeloperoxidase in tracheal aspirates from preterm infants: association with adverse respiratory outcome.

Authors:  I Hendrikje Buss; Revathy Senthilmohan; Brian A Darlow; Nina Mogridge; Anthony J Kettle; Christine C Winterbourn
Journal:  Pediatr Res       Date:  2003-03       Impact factor: 3.756

7.  A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human ceruloplasmin.

Authors:  S Pemberton; P Lindley; V Zaitsev; G Card; E G Tuddenham; G Kemball-Cook
Journal:  Blood       Date:  1997-04-01       Impact factor: 22.113

8.  Aceruloplasminemia: molecular characterization of this disorder of iron metabolism.

Authors:  Z L Harris; Y Takahashi; H Miyajima; M Serizawa; R T MacGillivray; J D Gitlin
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

9.  Iron metabolism in copper-deficient swine.

Authors:  G R Lee; S Nacht; J N Lukens; G E Cartwright
Journal:  J Clin Invest       Date:  1968-09       Impact factor: 14.808

10.  Characterization, mapping, and expression of the human ceruloplasmin gene.

Authors:  F Yang; S L Naylor; J B Lum; S Cutshaw; J L McCombs; K H Naberhaus; J R McGill; G S Adrian; C M Moore; D R Barnett
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

View more
  2 in total

1.  Immune evasion by a staphylococcal inhibitor of myeloperoxidase.

Authors:  Nienke W M de Jong; Kasra X Ramyar; Fermin E Guerra; Reindert Nijland; Cindy Fevre; Jovanka M Voyich; Alex J McCarthy; Brandon L Garcia; Kok P M van Kessel; Jos A G van Strijp; Brian V Geisbrecht; Pieter-Jan A Haas
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-14       Impact factor: 11.205

Review 2.  Molecular Functions of Ceruloplasmin in Metabolic Disease Pathology.

Authors:  Zhidong Liu; Miao Wang; Chunbo Zhang; Shigao Zhou; Guang Ji
Journal:  Diabetes Metab Syndr Obes       Date:  2022-03-03       Impact factor: 3.168

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.